BioPharmSignal logoBioPharmSignal

Biotech News

MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia

MeiraGTx (MGTX)MeiraGTx2026-06-25 13:46 ESTClinical readout

Clinically meaningful improvements in xerostomia symptoms measured by PRO Xerostomia Questionnaire (XQ) maintained out to 3 years post treatment with AAV-hAQP1 for both bilateral and unilateral cohorts Increases in Unstimulated Whole Saliva Flow Rate (UWSFR) maintained out to 3 years AAV-hAQP1 was

Open original release

Related news

MGTXMeiraGTx2026-06-25 13:46 EST

MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MGTXMeiraGTx2026-06-25 13:46 EST

MeiraGTx Reports First Quarter 2026 Financial and Operational Results

MGTXMeiraGTx2026-06-25 13:46 EST

MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

MGTXMeiraGTx2026-06-25 13:46 EST

MeiraGTx Reports Second Quarter 2025 Financial and Operational Results

MGTXMeiraGTx2026-06-25 13:46 EST

MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress

MGTXMeiraGTx2026-06-25 13:46 EST

MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology

MGTXMeiraGTx2026-06-25 13:46 EST

MeiraGTx Reports Third Quarter 2025 Financial and Operational Results

MGTXMeiraGTx2026-06-25 13:46 EST

MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational Results

MGTXMeiraGTx2026-06-25 13:46 EST

MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026

MGTXMeiraGTx2026-06-25 13:46 EST

MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)

View all latest news

MeiraGTx

MeiraGTx is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

MGTXMeiraGTx2026-06-26 11:27 EST

MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MGTXMeiraGTx2026-06-26 11:27 EST

MeiraGTx Reports First Quarter 2026 Financial and Operational Results

MGTXMeiraGTx2026-06-26 11:27 EST

MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

MGTXMeiraGTx2026-06-26 11:27 EST

MeiraGTx Reports Second Quarter 2025 Financial and Operational Results

MGTXMeiraGTx2026-06-26 11:27 EST

MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States